Scientific Reports · 2022 · 11 citations · 17 references
Life SciencesImmunologyImmunizationRheumatologyVaccinologyAutoantibodiesAutoimmune DiseasesAutoimmune InflammationAutoimmune Rheumatic DiseasesVaccinationVaccine EfficacyAntibodiesAntibody ImmunogenicityAutoimmune Disease VaccinesControl Group DesignMatched Control GroupSubunit Vaccine ImmunogenicityVaccine Response SerologyVaccine-induced Antibody Responses
Progress has been made in COVID-19 vaccine development, with encouraging safety and efficacy data. The purpose of this study was to investigate the immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). Patients with AIIRD (n = 101) were included in this study. All patients received 2 doses of inactivated COVID-19 vaccine. Serum anti-S1/RBD protein IgG was detected 2-16 weeks after the second vaccination. Seropositivity was defined as IgG ≥ 1.00 bound antibody unit S/CO. Immunogenicity of inactivated COVID-19 vaccine was assessed by seropositivity rate and the levels of serum IgG antibody against anti-S1/RBD protein, compared with the general population (n = 46). There was no difference by statistical significance in the seropositivity rate between patients with AIIRD (82.2%) and SLE (86.1%) and the control group (93.5%), p > 0.05. The level of anti-S1/RBD protein IgG antibodies in patients with AIIRD (median [IQR], 8.8 [2.2-17.3]) and SLE (median [IQR], 9.6 [2.4-20.4]) was comparable to that in the control group (median [IQR], 7.2 [3.1-14.2]), p > 0.05. Patients treated with glucocorticoids(GCs) (median dose, [IQR]: 2.5 mg/day [IQR 2.5-5.0]) or hydroxychloroquine(HCQ) or GCs + HCQ without other immunomodulatory medications, had an appropriate immunogenic response(88.1%) with high levels of anti-S1/RBD protein IgG(median [IQR], 12.1 [6.5-20.4]). Neither of patients treated with rituximab had positive serum antibodies, which was statistically significant, compared with the control group (p < 0.01). Compared with the control group, methotrexate(MTX) and iguratimod(IGU) was significantly reduced the level of anti-S1/RBD protein IgG antibodies. Inactivated COVID-19 vaccine had appropriate immunogenicity in patients with AIIRD. Immunogenicity of inactivated COVID-19 vaccine was severely impaired by rituximab, and also suppressed by MTX and IGU, while low doses of GC and HCQ had negligible effect.
17
Mine Durusu Tanrıöver, Levent Doğanay, Murat Akova et al. · The Lancet · 2021 · 929 citations · Full text
Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults
Nawal Al Kaabi, Yuntao Zhang, Shengli Xia et al. · JAMA · 2021 · 830 citations · Full text
Effect of an Inactivated Vaccine Against SARS-CoV-2 on Safety and Immunogenicity Outcomes
Shengli Xia, Kai Duan, Yuntao Zhang et al. · JAMA · 2020 · 806 citations · Full text
Victoria Furer, Tali Eviatar, Devy Zisman et al. · Annals of the Rheumatic Diseases · 2021 · 691 citations · Full text